Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinutuximab beta plus chemotherapy for refractory, relapsed or progressive neuroblastoma
2021-003832-96Phase 2Active
- Sponsor
- Jagiellonian University Medical College
- Start
- Sep 2021
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Dinutuximab beta in neuroblastoma, sponsored by Jagiellonian University Medical College. Primary endpoint: Safety endpoints. Started Sep 2021; status: active.
02
Drugs
Dinutuximab beta
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2021-003832-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003832-96.